Cumulative conception rates following gonadotropin therapy

Area of Science:

• Reproductive Endocrinology
• Infertility Treatment
• Human Reproduction

Background:

• Human menopausal gonadotropin (HMG) is a gonadotropic hormone preparation used to stimulate ovulation.
• Clomiphene citrate is a common first-line treatment for ovulation induction.
• Assessing factors influencing HMG efficacy is crucial for optimizing infertility management.

Purpose of the Study:

• To evaluate the efficacy of human menopausal gonadotropin (HMG) in achieving pregnancy in infertile women.
• To compare HMG treatment outcomes based on the presence or absence of endogenous estrogen activity.
• To analyze the impact of patient age on HMG treatment success rates.

Main Methods:

• A retrospective study of 515 infertile patients treated with HMG between 1963 and 1978.
• Patients were categorized into two groups: Group I (no endogenous estrogen activity) and Group II (presence of endogenous estrogen activity).
• Group II patients had previously failed clomiphene therapy; none had mechanical or male infertility factors.

Main Results:

• The cumulative pregnancy rate in Group I after six HMG cycles was 91.2%.
• For a second pregnancy in Group I, the cumulative conception rate was 93.6% after eight cycles.
• In Group II, the cumulative conception rate was 50% after 12 cycles of HMG treatment.
• Pregnancy rates were significantly higher in patients younger than 35 years in both groups.

Conclusions:

• HMG is a highly effective treatment for ovulation induction in infertile women, particularly those without endogenous estrogen activity.
• HMG offers a viable treatment option for patients who have not responded to clomiphene therapy.
• Age is a significant prognostic factor for HMG treatment success, with younger patients achieving better outcomes.